Li H, Zhang Z, Shi Z, Zhou S, Nie S, Yu Y
Cell Rep Med. 2025; 6(2):101927.
PMID: 39914384
PMC: 11866503.
DOI: 10.1016/j.xcrm.2024.101927.
Tan X, Wang S, Xiao G, Wu C, Liu X, Zhou B
J Clin Invest. 2024; 134(12).
PMID: 38662435
PMC: 11178546.
DOI: 10.1172/JCI176355.
Asadi M, Zarredar H, Zafari V, Soleimani Z, Saeedi H, Caner A
Cell Biochem Biophys. 2023; 82(1):107-118.
PMID: 37870699
DOI: 10.1007/s12013-023-01192-7.
Stanger B, Wahl G
Annu Rev Pathol. 2023; 19:397-421.
PMID: 37832945
PMC: 11486542.
DOI: 10.1146/annurev-pathmechdis-031621-025610.
Xiao G, Tan X, Rodriguez B, Gibbons D, Wang S, Wu C
Proc Natl Acad Sci U S A. 2023; 120(28):e2220276120.
PMID: 37406091
PMC: 10334751.
DOI: 10.1073/pnas.2220276120.
EMT-activated secretory and endocytic vesicular trafficking programs underlie a vulnerability to PI4K2A antagonism in lung cancer.
Tan X, Xiao G, Wang S, Shi L, Zhao Y, Liu X
J Clin Invest. 2023; 133(7).
PMID: 36757799
PMC: 10065074.
DOI: 10.1172/JCI165863.
PAX8 in the Junction between Development and Tumorigenesis.
Kakun R, Melamed Z, Perets R
Int J Mol Sci. 2022; 23(13).
PMID: 35806410
PMC: 9266416.
DOI: 10.3390/ijms23137410.
Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
Arnoletti J, Reza J, Rosales A, Monreal A, Fanaian N, Whisner S
PLoS One. 2022; 17(3):e0265725.
PMID: 35316296
PMC: 8939813.
DOI: 10.1371/journal.pone.0265725.
p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance.
Souza L, Faletti A, Verissimo C, Stelling M, Borges H
Membranes (Basel). 2022; 12(2).
PMID: 35207121
PMC: 8877489.
DOI: 10.3390/membranes12020202.
p53 loss activates prometastatic secretory vesicle biogenesis in the Golgi.
Tan X, Banerjee P, Shi L, Xiao G, Rodriguez B, Grzeskowiak C
Sci Adv. 2021; 7(25).
PMID: 34144984
PMC: 8213221.
DOI: 10.1126/sciadv.abf4885.
Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity.
Bota-Rabassedas N, Banerjee P, Niu Y, Cao W, Luo J, Xi Y
Cell Rep. 2021; 35(3):109009.
PMID: 33882319
PMC: 8142261.
DOI: 10.1016/j.celrep.2021.109009.
Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.
Li J, Yuan S, Norgard R, Yan F, Sun Y, Kim I
Cancer Discov. 2020; 11(3):736-753.
PMID: 33158848
PMC: 7933070.
DOI: 10.1158/2159-8290.CD-20-0519.
Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer.
Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W
Cancer Discov. 2020; 11(2):362-383.
PMID: 33158842
PMC: 7858239.
DOI: 10.1158/2159-8290.CD-20-0455.
Deconstructing tumor heterogeneity: the stromal perspective.
Vickman R, Faget D, Beachy P, Beebe D, Bhowmick N, Cukierman E
Oncotarget. 2020; 11(40):3621-3632.
PMID: 33088423
PMC: 7546755.
DOI: 10.18632/oncotarget.27736.
A protumorigenic secretory pathway activated by p53 deficiency in lung adenocarcinoma.
Tan X, Shi L, Banerjee P, Liu X, Guo H, Yu J
J Clin Invest. 2020; 131(1).
PMID: 32931483
PMC: 7773359.
DOI: 10.1172/JCI137186.
Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma.
Jia W, Rajani C, Xu H, Zheng X
Protein Cell. 2020; 12(5):374-393.
PMID: 32797354
PMC: 8106555.
DOI: 10.1007/s13238-020-00748-0.
Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome.
Capaci V, Bascetta L, Fantuz M, Beznoussenko G, Sommaggio R, Cancila V
Nat Commun. 2020; 11(1):3945.
PMID: 32770028
PMC: 7414119.
DOI: 10.1038/s41467-020-17596-5.
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Li J, Yuan S, Norgard R, Yan F, Yamazoe T, Blanco A
Cancer Immunol Res. 2019; 8(3):282-291.
PMID: 31871120
PMC: 7173406.
DOI: 10.1158/2326-6066.CIR-19-0661.
